Association between proton pump inhibitor use and mortality in patients with hepatocellular carcinoma receiving tyrosine kinase inhibitor
Gut
.
2020 Sep 9:gutjnl-2020-321932.
doi: 10.1136/gutjnl-2020-321932.
Online ahead of print.
Authors
Chun-Ying Wu
1
2
,
Hsiu J Ho
3
,
Chen-Yi Wu
4
,
Yi-Ju Chen
5
,
Teng-Yu Lee
6
,
Yao-Chun Hsu
7
,
Jaw-Town Lin
8
Affiliations
1
Institute of Biomedical Informatics, School of Medicine, National Yang-Ming University, Taipei, Taiwan
[email protected]
.
2
Division of Translational Research, Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan.
3
Institute of Biomedical Informatics, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
4
Institute of Public Health, National Yang-Ming University, Taipei, Taiwan.
5
Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan.
6
Division of Gastroenterology & Hepatology, Taichung Veterans General Hospital, Taichung, Taiwan.
7
Division of Gastroenterology, E-Da Hospital, Yanchao, Kaohsiung, Taiwan.
8
Digestive Medicine Center, China Medical University, Taichung, Taiwan.
PMID:
32907829
DOI:
10.1136/gutjnl-2020-321932
No abstract available
Keywords:
antibody targeted therapy; hepatoma; proton pump inhibition.
Publication types
Letter